Physician profile
Maya Miley
NPI 1548440670
$3,285.60
in general payments reported to CMS, 2019-2025
33 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.20 · 2020: $651 · 2021: $504 · 2022: $747 · 2023: $559 · 2024: $337 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.48 | 2021-2025 | |
| Lilly USA, LLC | $336.74 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $276.01 | 2020-2025 | |
| Novo Nordisk INC | $260.05 | 2020-2025 | Ozempic, Rybelsus |
| Penumbra, INC. | $241.55 | 2022-2024 | Penumbra Coil 400 |
| Astrazeneca Pharmaceuticals Lp | $234.18 | 2021-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.70 | 2021-2025 | Jardiance |
| Mannkind Corporation | $161.32 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $139.69 | 2020-2023 | |
| Allergan, INC. | $137.34 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $107.43 | 2022-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $101.35 | 2023-2024 | Nuedexta |
| Clarus Therapeutics INC. | $83.39 | 2021 | |
| Corcept Therapeutics | $59.05 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.72 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $53.59 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $52.90 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $50.34 | 2023-2024 | Quviviq |
| Aytu Biopharma, INC. | $44.72 | 2019-2020 | |
| Astellas Pharma US INC | $40.68 | 2021 | |
| Amgen INC. | $33.67 | 2023 | Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $29.62 | 2024 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.86 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $25.12 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $24.70 | 2022 | |
| Dexcom, INC. | $22.75 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $20.44 | 2021 | |
| Gilead Sciences, INC. | $19.65 | 2021 | |
| Glaxosmithkline, LLC. | $17.18 | 2022 | |
| Horizon Therapeutics Plc | $15.85 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.29 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.21 | 2021 | |
| Merck Sharp & Dohme LLC | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Miley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.